Lobbying disclosures · Lobbying report
ABT: second_quarter 2026 lobbying report
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula. Proposals related to Medicare coverage of continuous glucose monitors. Issues related to cancer diagnostics national coverage determination. H.R.3512 - Tackling Predatory Litigation Funding Act. Issues related to TRICARE coverage of diabetes management devices.
Follow ABT- Became public
- Jul 9, 2026, 6:18 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 8, 2026, 9:48 AM EST
Why this is connected
Exact legal-name match: ABBOTT LABORATORIES (https://www.sec.gov/Archives/edgar/data/1800/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/146ad32b-2bca-4861-9edf-c9f71780e040/","filing_uuid":"146ad32b-2bca-4861-9edf-c9f71780e040","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/146ad32b-2bca-4861-9edf-c9f71780e040/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-09T06:18:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"611 2nd Street, NE","registrant_address_2":"Suite 1","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":401105121,"url":"https://lda.gov/api/v1/registrants/401105121/","house_registrant_id":44305,"name":"MARSHALL & POPP, LLC","description":"​Government affairs and consulting firm.","address_1":"611 2nd Street, NE","address_2":"Suite 1","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-321-1811","dt_updated":"2026-07-13T16:40:37.032909-04:00"},"client":{"id":65130,"url":"https://lda.gov/api/v1/clients/65130/","client_id":65130,"name":"ABBOTT LABORATORIES","general_description":"Health care company with medical devices, diagnostics and nutrition.","client_government_entity":null,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-02-07"},"lobbying_activities":[{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":"Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles","new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Proposals related to Medicare coverage of continuous glucose monitors. Issues related to cancer diagnostics national coverage determination.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R.3512 - Tackling Predatory Litigation Funding Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to TRICARE coverage of diabetes management devices.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in ABT
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 30, 2026$1K–$15K
Rep. Thomas H. Kean, Jr. (R-NJ-7)
Sold (partial) Abbott Laboratories ABT
$1K–$15K · Traded Sep 17, 2026 · disclosed Oct 30, 2026
Committee overlap: Energy and Commerce - Oct 27, 2026$50K–$100K
Rep. Pete Sessions (R-TX-17)
$50K–$100K · Traded Oct 2, 2026 · disclosed Oct 27, 2026 · Spouse
- Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Abbott Laboratories ABT
$1K–$15K · Traded Sep 18, 2026 · disclosed Oct 12, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Abbott Laboratories ABT
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 18, 2026$15K–$50K
Rep. Rick W. Allen (R-GA-12)
$15K–$50K · Traded Jul 14, 2026 · disclosed Aug 18, 2026 · Spouse
Committee overlap: Energy and CommerceTraded 2 days before earnings - Aug 14, 2026$1K–$15K
Rep. Richard McCormick (R-GA-7)
$1K–$15K · Traded Jul 30, 2026 · disclosed Aug 14, 2026
Got $2K from the company’s PAC - Aug 12, 2026$1K–$15K
Rep. Mike Kelly (R-PA-16)
$1K–$15K · Traded Jul 17, 2026 · disclosed Aug 12, 2026 · Spouse
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
Sold (full) Abbott Laboratories ABT
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.